in vitro phenotypic assays for Parkinson’s disease
Supported by:
7 March 2018
ABOUT THIS WEBINAR:
The discovery and validation of novel targets are essential to fuel a healthy drug pipeline, and in vitro phenotypic assays are instrumental for delivering valid targets and promising lead molecules.
View this webinar to learn more about our in vitro assay capabilities performed in clinically relevant cell models, where we’ll highlight key endpoints for neurodegenerative diseases such as a-synuclein aggregation, Ab toxicity and autophagy/mitophagy readouts.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Assays, Cell-based assays, CRISPR, Drug Discovery, Drug Discovery Processes, In Vitro, Neurosciences, Research & Development, RNAs, Stem Cells
Related organisations
Charles River Laboratories
